Biased small‐molecule ligands for selective inhibition of HIV‐1 cell entry via CCR5

Since the discovery of HIV's use of CCR5 as the primary coreceptor in fusion, the focus on developing small‐molecule receptor antagonists for inhibition hereof has only resulted in one single drug, Maraviroc. We therefore investigated the possibility of using small‐molecule CCR5 agonists as HIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Berg, Christian, Spiess, Katja, Lüttichau, Hans R., Rosenkilde, Mette M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226280/
https://www.ncbi.nlm.nih.gov/pubmed/28097000
http://dx.doi.org/10.1002/prp2.262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226280/
https://www.ncbi.nlm.nih.gov/pubmed/28097000
http://dx.doi.org/10.1002/prp2.262

Ejemplares similares